2026 Breakthrough Prizes Honor Gene Therapies and Cures
A list of things that belong together: a gene, a switch, a single letter of DNA code. A virus, a light-sensitive protein, a child seeing her mother’s face for the first time. A muon spinning in a magnetic field, a measurement so precise it could break the laws of physics. A wave equation that explodes in finite time. A woman physicist, two years past her PhD, holding a new prize named for the woman who discovered evidence of dark matter.
These are the 2026 Breakthrough Prizes. They form a pattern: $3 million each, six awards, one ceremony. But the pattern runs deeper than money.
The Hemoglobin Switch
Stuart Orkin and Swee Lay Thein spent decades asking a single question: why does the human body stop making foetal haemoglobin after birth? Every baby is born with it. It carries oxygen perfectly. Then, around six months of age, a genetic switch flips. The body begins making adult haemoglobin instead. For most people, this is fine. For people with sickle cell disease or beta-thalassemia, it is a death sentence.
Sickle cell disease twists red blood cells into crescents. They clog vessels. They cause pain so severe it has been described as being stabbed repeatedly. Beta-thalassemia destroys red blood cells so fast that patients need transfusions every few weeks. Both diseases are caused by mutations in the beta-globin gene of adult haemoglobin. The foetal version works fine. The problem is that the body stops making it.
Orkin, at Boston Children’s Hospital and Harvard Medical School, found the master switch: a protein called BCL11A [1][2]. It turns off the foetal haemoglobin gene after birth. Thein, at the University of Oxford and later the National Institutes of Health, found the genetic variations that naturally keep foetal haemoglobin switched on in some people [3][4]. Together, their work revealed a target.
If you could disable BCL11A in a patient’s blood stem cells, the cells would keep making foetal haemoglobin for life. The disease would become invisible.
That is exactly what Casgevy does. It is the first CRISPR-based medicine ever approved for any disease, anywhere in the world. The treatment works like this: doctors take stem cells from the patient’s bone marrow. They use CRISPR to edit the BCL11A gene. They infuse the edited cells back. The cells settle in the bone marrow. They start producing foetal haemoglobin. The patient is cured.
The first approvals came in 2023, in the United Kingdom and the United States [5]. By 2026, hundreds of patients have been treated. The results have been described as transformative. Children who spent their lives in hospitals now run. Adults who expected to die young now plan for retirement.
Orkin and Thein share one of the three Life Sciences prizes this year. Their work is a direct line from a basic biological observation — why do babies have different blood? — to a cure that changes the lives of millions.
The First Gene Therapy
Jean Bennett, Katherine High, and Albert Maguire worked on a different problem. Leber congenital amaurosis is a rare inherited disease that destroys the retina. Children born with it have severe vision loss from birth. Most are completely blind by early adulthood. The cause is a single mutated gene, called RPE65. It produces a protein essential for light detection. Without it, the retina cannot function.
The three researchers developed a way to deliver a working copy of the gene directly into the retina. They used a harmless virus — an adeno-associated virus — as a delivery vehicle. They injected it under the retina. The virus carried the correct gene into the cells. The cells began producing the missing protein. Vision returned.
This was the first gene-replacement therapy approved by the U.S. Food and Drug Administration [5]. It was approved in 2017. By 2026, hundreds of eligible patients in the United States have been treated. The benefits last more than a decade. Children who would have gone blind can now read, play, and live independently.
But the impact goes beyond one disease. Bennett, High, and Maguire established the regulatory pathways for gene therapy. They showed the FDA how to evaluate safety and efficacy for a treatment that puts new genes into human cells. Every gene therapy approved since — for spinal muscular atrophy, for hemophilia, for certain cancers — stands on the foundation they built.
The Common Mutation
Rosa Rademakers and Bryan Traynor each found the same thing, independently, in 2011. They were studying two devastating diseases: amyotrophic lateral sclerosis (ALS), which paralyses the body while leaving the mind intact, and frontotemporal dementia, which destroys personality and language while leaving the body intact. For decades, scientists thought they were separate. Rademakers and Traynor showed they share a cause.
Both groups found a mutation in a gene called C9orf72. The mutation is a repeat expansion — a stutter in the DNA where six letters repeat hundreds or thousands of times. In healthy people, the sequence repeats only a few times. The mutation accounts for roughly one-third of all familial cases of both diseases in European populations. It is the most common genetic cause ever found for either condition.
The discovery changed everything. Genetic tests became available for families. Researchers could create animal models. Drug companies could target the specific mechanism. Clinical trials began. By 2026, several experimental treatments are in late-stage testing.
Rademakers, at the Mayo Clinic in Florida, and Traynor, at the National Institutes of Health and later University College London, share the third Life Sciences prize [4]. Their work connects two diseases that were thought to be unrelated. It shows that a single genetic glitch can cause radically different symptoms depending on where and when it activates in the brain.
The Wave That Breaks
Frank Merle works on the mathematics of how things change. Not just any change — the kind described by partial differential equations, which govern how waves move, how fluids flow, how energy spreads. For decades, mathematicians believed that certain equations were stable. They thought solutions would behave predictably. Merle proved them wrong.
He showed that equations long thought to be stable can become infinite in finite time. A wave can grow without bound. A system can explode. This is not just abstract. These equations describe real phenomena: the collapse of a star, the turbulence in a jet engine, the spread of a forest fire. Understanding when and how solutions blow up is essential for predicting real-world disasters.
Merle, a mathematician at the University of Cergy-Pontoise and the Institut des Hautes Études Scientifiques, receives the Mathematics prize [6][7]. His work overturned assumptions that had stood for generations. It opened new questions about what stability really means.
The Muon’s Spin
Three collaborations — at CERN in Europe, Brookhaven National Laboratory in the United States, and Fermilab in the United States — share the Fundamental Physics prize [8][9]. They have spent decades measuring one number: the magnetic moment of the muon.
The muon is a subatomic particle, a heavier cousin of the electron. It spins. Because it spins, it has a magnetic field. The strength of that field is predicted by the Standard Model of particle physics, our best theory of how matter works. But the prediction depends on quantum fluctuations — virtual particles that pop in and out of existence. If the measurement disagrees with the prediction, it means there are particles or forces we do not know about.
The experiments measure the muon’s magnetic moment with extraordinary precision. The Brookhaven experiment, which ran from 1997 to 2001, found a hint of a discrepancy [9]. The Fermilab experiment, which ran from 2018 to 2023, confirmed it with higher precision. The CERN experiment, which began in the 1970s, laid the groundwork [8]. Combined, the results show a persistent difference between measurement and prediction.
This could be the first evidence of new physics beyond the Standard Model. It could reveal unknown particles, extra dimensions, or forces we have never seen. The prize recognizes the decades of work required to achieve this precision — building the magnets, tracking the muons, calculating the corrections.
A Lifetime of Force
David Gross receives a Special Breakthrough Prize for a lifetime of contributions to theoretical physics. In 1973, he helped develop the theory of the strong nuclear force, which holds the atomic nucleus together. The theory, called quantum chromodynamics, explains how quarks bind into protons and neutrons. It is one of the pillars of the Standard Model.
Gross, at the University of California, Santa Barbara, has also contributed to string theory, the study of black holes, and the nature of space and time. The special prize recognizes that some contributions are too large to fit into a single category.
The New Frontier
The foundation announced a new prize this year: the Vera Rubin New Frontiers Prize. It is named for the astronomer who discovered dark matter by measuring how galaxies spin. The prize is for women physicists within two years of their PhD. The first recipient is Carolina Figueiredo of Princeton University.
Fifteen early-career researchers share six New Horizons Prizes in physics and mathematics. Three women mathematicians receive the Maryam Mirzakhani New Frontiers Prize, named for the first woman to win the Fields Medal.
These prizes are not afterthoughts. They are investments. The Breakthrough Prizes have now awarded more than $340 million to scientists since their founding 14 years ago. The new prizes ensure that the next generation — particularly women and early-career researchers — have a path forward.
The Ceremony
The laureates will be celebrated at a ceremony in Los Angeles. The show will premiere on YouTube on April 26. It will feature celebrities, scientists, and the families whose lives have been changed.
A list of things that belong together: a child seeing light for the first time. A patient walking out of a hospital without pain. A mathematician watching an equation explode. A muon spinning in a magnetic field. A woman physicist, two years past her PhD, holding a prize named for the woman who found dark matter.
The pattern is complete. But the world has changed since the first paragraph. The cures are real. The measurements are precise. The questions are deeper. The next generation is already at work.
Sources
4. National Institutes of Health
5. U.S. Food and Drug Administration
6. University of Cergy-Pontoise
7. Institut des Hautes Études Scientifiques
8. CERN